FINASTERID 5MG TBL FLM 100 Stk (FINASTERID)

Finasteride-Teva is indicated only for adult men over 18 years of age.
• Treatment and control of benign prostatic hyperplasia (BPH), prevention of urological complications with the aim of:
– reducing the risk of acute urinary retention;
– reducing the risk of the need for surgical interventions, including transurethral resection of the prostate and prostatectomy.
• Treatment to reduce the size of an enlarged prostate gland, improve urine flow, and reduce symptoms associated with BPH.
• In combination with the alpha blocker doxazosin to reduce the risk of progression of symptoms associated with BPH.

The use of Finasteride-Teva is contraindicated during pregnancy and in women of childbearing age. Due to the ability of type II 5-alpha reductase inhibitors to suppress the conversion of testosterone to dihydrotestosterone, these drugs, including finasteride, when used in pregnant women, can cause abnormalities in the development of the external genitalia in the male fetus.
Finasteride-Teva drug not indicated for use in women. There is no data on the excretion of finasteride into breast milk.

• Hypersensitivity to finasteride and/or to any of the excipients in the drug.
• According to its registered indication, Finasteride-Teva is not indicated for use in women, children and adolescents under 18 years of age (see section “Use during pregnancy and breastfeeding”).
• Rare hereditary galactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.

With caution
Patients with a large volume of residual urine and/or significantly reduced urine outflow should be regularly monitored by a doctor to detect obstructive uropathy.
The drug is prescribed with caution to patients with liver failure and the elderly.